期刊文献+

结直肠癌免疫治疗生物标志物的研究进展 被引量:6

暂未订购
导出
摘要 结直肠癌(CRC)是一种异质性疾病,治疗主要是以细胞毒性药物化疗为主。通过对其发病机制的研究发现存在很多表观遗传及遗传性因素。某些特异性生物标志物可以比肿瘤分期更好地预测临床表现及其预后。对患者进行常规分子检测有利于筛选出适合接受靶向药物及免疫治疗的患者。通过对KRAS、NRAS和BRAF突变的检测,DNA错配修复状态、肿瘤浸润淋巴细胞和检查点蛋白表达的分析有助于判断患者是否能从免疫治疗中获益。本文重点对CRC中一些相关的用于免疫治疗的生物标志物进行综述。
作者 于月 耿敬姝
出处 《癌症进展》 2017年第9期998-1002,共5页 Oncology Progress
  • 相关文献

参考文献4

二级参考文献83

  • 1Jose Perea,Edurne Alvaro,Yolanda Rodríguez,Cristina Gravalos,Eva Sánchez-Tomé,Barbara Rivera,Francisco Colina,Pablo Carbonell,Rogelio González-Sarmiento,Manuel Hidalgo,Miguel Urioste.Approach to early-onset colorectal cancer:Clinicopathological,familial,molecular and immunohistochemical characteristics[J].World Journal of Gastroenterology,2010,16(29):3697-3703. 被引量:3
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,2006,6(1):4.
  • 3Kotepui M, Piwkham D, Songsri A, et al. Histopathology analysis of benign colorectal diseases and colorectal cancer in Hatyai Hospital, Songkhla, Thailand [J]. Asian Pac J Cancer Prey, 2013, 14 (4) : 2667 - 2671.
  • 4Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of coloreetal cancer [ Jl. N Engl J Med, 2009, 361 (25) : 2449 - 2460.
  • 5Wei W, Liu F, Liu L, et al. Distinct mutations in MLH1 and MSH2 genes in hereditary non- polyposis colorectal cancer (HNPCC) families from China [J]. BMB Rep, 2011, 44 (5): 317-322.
  • 6Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carders and noncarriers from families with a DNA mismatch re- pair gene mutation: a prospective cohort study [ J ]. J Clin Oncol, 2012, 30 (9): 958-964.
  • 7Poynter JN, Siegmund KD, Weisenberger D J, et al. Molecular char- acterization of MSI - H colorectal cancer by MLHI promoter methyla- tion, immunohistochemistry, and mismatch repair germline mutation screening [ J ]. Cancer Epidemiol Biomarkers Prey, 2008, 17 (11): 3208 -3215.
  • 8Zhang H, Fu WL, Huang Q. Mapping of the methylation pattern of the hMSH2 promoter in colon cancer, using bisulfite genomic sequen- cing EJ]- J Carcinog, 2006, 5: 22.
  • 9Shia J. Immunohistochemistry versus microsatellite instability testing for screening'colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochem- istry [J]. J Mol Diagn, 2008, 10 (4): 293-300.
  • 10Merok MA, Ahlquist T, Rcyrvik EC, et al. Microsatellite instability has a positive prognostic impact on stage IT colorectal cancer after com- plete resection: results from a large, consecutive Norwegian series [J]. Ann Oncol, 2013, 24 (5): 1274-1282.

共引文献38

同被引文献70

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部